By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Nanosphere reported after the close of the market Wednesday that its third-quarter revenues rose nearly 50 percent year over year. The increase was made up solely of product sales, largely to international buyers, the company said.

The Northbrook, Ill.-based molecular diagnostics firm brought in total revenues of $556,000 for the three-month period ended Sept. 30, up from $374,000 for Q3 2010.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

While gene therapies may have high price tags, they could be cheaper than the cost of managing disease, according to MIT's Technology Review.

Researchers are looking for markers that indicate which cancer patients may respond to immunotherapies, the Associated Press writes.

In Nature this week: paternal age associated with de novo mutations in children, and more.

Nature News writes that researchers are still wrangling over the role of the p-value.